Renalytix Plc (LON:RENX – Get Free Report)’s stock price shot up 0.7% on Tuesday. The company traded as high as GBX 6.30 and last traded at GBX 6.19. 1,651,882 shares traded hands during trading, an increase of 52% from the average session volume of 1,085,369 shares. The stock had previously closed at GBX 6.15.
Renalytix Price Performance
The company’s fifty day moving average price is GBX 4.40 and its 200 day moving average price is GBX 2.91. The company has a debt-to-equity ratio of -483.33, a quick ratio of 2.42 and a current ratio of 1.57. The firm has a market capitalization of £27.05 million, a price-to-earnings ratio of -1.55 and a beta of 1.81.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Stories
- Five stocks we like better than Renalytix
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
